Latest News
Crescent Energy Surges on Oil Price Spike, Boosts Buyback Plan
Crescent Energy shares advanced sharply in premarket trading Monday, approaching a 52-week high after crude oil prices jumped on escalating Middle East conflict concerns. The company also increased its share buyback authorization to $400 million.
Crescent Energy Surges on Oil Price Spike, Boosts Buyback
Crescent Energy shares advanced sharply in premarket trading Monday, approaching a 52-week high following a surge in crude oil prices driven by geopolitical tensions. The company also announced an expanded share buyback program.
Sasol Rallies on Oil Price Surge Amid Middle East Tensions
Sasol Ltd shares advanced sharply as geopolitical tensions drove oil prices higher, though the rally faced headwinds from a weaker rand and an adverse arbitration ruling.
Sasol Surges on Oil Price Spike Amid Middle East Tensions
Sasol Ltd. shares advanced sharply as Brent crude oil prices surged to a 13-month high amid Middle East supply concerns. The South African energy and chemicals firm also faces an arbitration ruling in an ethylene pricing dispute.
Sasol Surges on Oil Price Spike Amid Geopolitical Tensions
Sasol Ltd advanced sharply as Brent crude oil prices surged to levels not seen since January 2025, driven by geopolitical tensions. The stock reached a 52-week high before paring gains.
Accelerant Stock Retreats in Premarket Following Friday's Surge
Accelerant Holdings stock declined nearly 3% in premarket trading, giving back a portion of its sharp 10% rally from Friday. The market now focuses on the company's upcoming audited financial release and forward outlook.
Accelerant Stock Retreats in Premarket Following Friday's Surge
Accelerant Holdings stock declined nearly 3% in premarket trading Monday, paring back a significant 10% surge from the previous session. Investors are focused on the company's upcoming audited financial results and 2026 guidance scheduled for March 19.
Accelerant Stock Retreats in Premarket Following Friday's Surge
Accelerant Holdings stock declined nearly 3% in premarket activity, paring a sharp rally from the prior session. The market now focuses on the company's upcoming audited financial release and forward outlook.
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.
BioCryst Shares Slip on New Hereditary Angioedema Drug Data
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.
